|Bid||3.2200 x 1100|
|Ask||3.2300 x 1300|
|Day's Range||3.2200 - 3.8800|
|52 Week Range||0.6900 - 6.9300|
|Beta (5Y Monthly)||2.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that results from a Phase 4 study of VBI’s prophylactic 3-antigen hepatitis B virus (HBV) vaccine in younger adults were published in Vaccine, a journal publication from Elsevier. The study was designed to evaluate the immunogenicity of VBI’s 3-antigen HBV vaccine in support of the qualification of that batch as a new reference standard for vaccine release to the Israeli market, where VBI’s vaccine is available as Sci-B-Vac®.
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for the Company’s 3-antigen prophylactic hepatitis B vaccine candidate for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults. The acceptance of the MAA filing begins the EMA’s review process.
Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.